Scarica l'app Stockscreener
1.49
4.49%
-0.07
Dopo l'orario di chiusura:
1.47
-0.02
-1.34%
Precedente Chiudi:
$1.56
Aprire:
$1.54
Volume 24 ore:
161.59K
Relative Volume:
1.14
Capitalizzazione di mercato:
$40.60M
Reddito:
-
Utile/perdita netta:
$-14.14M
Rapporto P/E:
-1.8625
EPS:
-0.8
Flusso di cassa netto:
$-12.64M
1 W Prestazione:
-11.31%
1M Prestazione:
-30.37%
6M Prestazione:
-51.47%
1 anno Prestazione:
-56.43%
Intervallo 1D:
$1.429
$1.56
Intervallo di 1 settimana:
$1.429
$1.72
Portata 52W:
$1.429
$7.75
Immix Biopharma Inc Stock (IMMX) Company Profile
Nome
Immix Biopharma Inc
Settore
Industria
Telefono
(888) 958-1084
Indirizzo
11400 WEST OLYMPIC BLVD., LOS ANGELES
Immix Biopharma Inc Borsa (IMMX) Ultime notizie
Immix Biopharma stock hits 52-week low at $1.51 amid market challenges - Investing.com India
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN
Immix Biopharma stock hits 52-week low at $1.74 amid market challenges - Investing.com Australia
Immix Biopharma stock hits 52-week low at $1.74 amid market challenges - Investing.com Canada
Immix Biopharma stock hits 52-week low at $1.74 amid market challenges - Investing.com
Immix Biopharma Announces Dr. Raymond Comenzo, - GlobeNewswire
Immix Biopharma gains AL Amyloidosis expert for advisory board - Investing.com
Immix Biopharma gains AL Amyloidosis expert for advisory board By Investing.com - Investing.com Australia
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board - StockTitan
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update - MarketBeat
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update - Defense World
It would be worthwhile to take a closer look at Immix Biopharma Inc (IMMX) - US Post News
Its Stock Has Paid Off Big Time For Immix Biopharma Inc - SETE News
The Attractiveness of Investing In Immix Biopharma Inc (IMMX) is Growing - Knox Daily
Immix Biopharma Independent Director Acquires 2.6% More Stock - Yahoo Finance UK
Immix Biopharma Independent Director Acquires 2.6% More Stock - Yahoo Finance
Insider Spends US$52k Buying More Shares In Immix Biopharma - Simply Wall St
Immix Biopharma expands clinical trial sites for AL Amyloidosis therapy - Investing.com
Immix Biopharma expands clinical trial sites for AL Amyloidosis therapy By Investing.com - Investing.com Canada
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - GlobeNewswire
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - The Bakersfield Californian
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - StockTitan
The markets will rise or fall with NVDA - RagingBull
Immix Biopharma director Jason Hsu buys $51,623 in company stock - Investing.com
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Immix Biopharma Inc’s latest rating changes from various analysts - Knox Daily
Q3 2024 Earnings Estimate for Immix Biopharma, Inc. Issued By HC Wainwright (NASDAQ:IMMX) - MarketBeat
HC Wainwright Weighs in on Immix Biopharma, Inc.’s Q3 2024 Earnings (NASDAQ:IMMX) - Defense World
Immix Biopharma, Inc. (NASDAQ:IMMX) Director Carey Ng Purchases 10,000 Shares of Stock - Defense World
Immix Biopharma, Inc. (NASDAQ:IMMX) Director Purchases $18,600.00 in Stock - MarketBeat
Immix Biopharma, Inc. to Post FY2024 Earnings of ($0.61) Per Share, Edison Inv. Res Forecasts (NASDAQ:IMMX) - MarketBeat
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 7.5% in July - MarketBeat
What Makes Immix Biopharma (IMMX) a New Buy Stock - MSN
What Makes Immix Biopharma (IMMX) a New Buy Stock - Yahoo Finance
Immix Biopharma (NASDAQ:IMMX) Rating Reiterated by HC Wainwright - MarketBeat
HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - Defense World
FY2024 Earnings Forecast for Immix Biopharma, Inc. (NASDAQ:IMMX) Issued By Edison Inv. Res - Defense World
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024 - InvestorPlace
Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - Simply Wall St
Monitoring Immix Biopharma Inc (IMMX) after recent insider movements - Knox Daily
Jason Hsu Purchases 6,000 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) Stock - Defense World
Immix Biopharma director Jason Hsu buys $19.5k in company shares - Investing.com Australia
Immix Biopharma director Jason Hsu buys $19.5k in company shares - Investing.com
Immix Biopharma director Jason Hsu buys $19.5k in company shares - Investing.com UK
Immix Biopharma director Jason Hsu buys $19.5k in company shares - Investing.com Canada
Immix BiopharmaUS$8m grant to advance novel CAR-T treatment - Smartkarma
HC Wainwright Reiterates “Buy” Rating for Immix Biopharma (NASDAQ:IMMX) - Defense World
Immix Biopharma (NASDAQ:IMMX) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) - StockTitan
California Institute for Regenerative Medicine Awards - GlobeNewswire
Immix Biopharma Inc Azioni (IMMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
4.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):